Lucid Diagnostics reports Q4 adjusted EPS (10c) vs. (19c) last year

Reports Q4 revenue $1.5M vs. $1.2B last year. Lucid had cash and cash equivalents of $34.7M as of December 31, 2025 vs. $22.4M as of December 31, 2024. “Throughout 2025, we established a strong commercial foundation for EsoGuard, demonstrating that we can consistently generate and sustain demand, drive physician adoption, and engage effectively with both health systems and commercial payors,” said CEO Lishan Aklog. “As we move into 2026, our focus is on building on that foundation by converting demand into revenue, with priorities including deepening our relationship with the VA, expanding adoption across health systems, advancing coverage with commercial payors, and securing Medicare coverage, which we still expect in the near-term.”